Caribou Biosciences, Inc., was incorporated in Delaware in October 2011. The Company is a clinical-stage biopharmaceutical company focused on developing allogeneic CAR-T cell therapies for hematological malignancies using its proprietary chRDNA genome editing technology. Its lead drug candidates vispacabtagene regedleucel (vispa-cel) and CB-011 are designed to provide broad patient accessibility and rapid treatment as spot-based products. 

Investors seek stocks with high earnings beat potential ahead of earnings season. Five top-ranked stocks identified by a screener are The Allstate Corporation, Wayfair, BILL Holdings, Twilio, and Caribou Biosciences. Historically, stocks with solid earnings growth tend to outperform those with weak earnings growth or those that meet market expectations. Analysts project earnings based on a company's financials and initiatives, and outperforming estimates is equivalent to beating the company's own expectation and market perception. Stocks with a track record of impressive earnings surprise history tend to perform well.

The Allstate

Wayfair

BILL Holdings

Caribou Biosciences

Twilio

Earnings Surprise Catalyst: Top 5 Stocks to Watch

Caribou Biosciences:B of A Securities maintains Buy rating with $5.00 PT.

Caribou Biosciences, a clinical-stage CRISPR genome-editing biopharmaceutical company, announced that CEO Rachel Haurwitz will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026. The company is focused on developing transformative therapies for patients with devastating diseases, including off-the-shelf CAR-T cell therapies for hematologic malignancies.

Caribou Biosciences to Present at H.C. Wainwright Cell Therapy Virtual Conference

Caribou Biosciences reported long-term vispa-cel data in second-line large B cell lymphoma patients at EHA 2026. Single-dose vispa-cel achieved an 82% overall response rate, 67% complete response rate, and 17.1-month median progression-free survival. The therapy was generally well-tolerated, supporting outpatient administration and further expansion to community centers. The ANTLER-3 trial is designed to address unmet needs in second-line LBCL patients at academic and community centers.Caribou Biosciences presented long-term data on vispa-cel in second-line large B cell lymphoma (LBCL) patients at the European Hematology Association (EHA) 2026 conference. The single-dose therapy demonstrated an 82% overall response rate and a 67% complete response rate, with a <a href="https://example.com">median progression-free survival of 17.1 months</a>. The treatment was generally well-tolerated, supporting its potential for outpatient administration and broader deployment to community centers. These findings reinforce the therapy’s safety and efficacy profile, which could facilitate wider adoption across diverse clinical settings.The ANTLER-3 trial is currently underway to further evaluate vispa-cel in second-line LBCL patients, with enrollment taking place at both academic and community centers. This trial aims to address existing treatment gaps in this patient population. The data presented at EHA 2026 provide additional insights into the long-term outcomes of vispa-cel, contributing to the growing evidence base for this novel therapy.

CaribouBiosciences

Caribou Biosciences Reports Vispa-cel Data in Second-line LBCL at EHA 2026

Vispa-cel, a CD19-targeted CAR-T cell therapy, has shown durable long-term responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). The therapy produced an 82% overall response rate, 67% complete response rate, and 17.1-month median progression-free survival. The safety profile was generally well-tolerated, supporting outpatient administration and expansion to community centers. A pivotal phase 3 trial, ANTLER-3, is underway to address the unmet need in 2L LBCL patients.Vispa-cel, an allogeneic anti-CD19 CAR-T cell therapy developed by Caribou Biosciences, has demonstrated durable responses in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). As of September 29, 2025, the therapy achieved an 82% overall response rate (ORR) and a 64% complete response (CR) rate in the confirmatory cohort of the ANTLER phase 1 trial, with a <a href="https://www.onclive.com/view/vispa-cel-shows-comparable-efficacy-durability-to-autologous-car-t-cell-therapy-in-r-r-b-cell-nhl">12-month progression-free survival rate</a> of 51%. In the optimized profile cohort, which included patients receiving vispa-cel manufactured from young donor-derived T cells with at least 2 HLA allele matches, the ORR was 86%, with a <a href="https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-positive-data-antler-phase-1-trial">63% CR rate and</a> a 12-month PFS rate of 53%. The <a href="https://www.onclive.com/view/vispa-cel-shows-comparable-efficacy-durability-to-autologous-car-t-cell-therapy-in-r-r-b-cell-nhl">longest responding patient remained</a> in complete remission three years post-infusion.The safety profile of vispa-cel was generally favorable, with common adverse events including thrombocytopenia (62%), cytokine release syndrome (55%), and anemia (52%). Notably, <a href="https://www.onclive.com/view/vispa-cel-shows-comparable-efficacy-durability-to-autologous-car-t-cell-therapy-in-r-r-b-cell-nhl">no cases of graft-versus-host disease</a> or grade 3 or higher immune effector cell–associated neurotoxicity syndrome (ICANS) were observed in the confirmatory or optimized profile cohorts. These findings support the <a href="https://www.onclive.com/view/vispa-cel-shows-comparable-efficacy-durability-to-autologous-car-t-cell-therapy-in-r-r-b-cell-nhl">potential for outpatient administration</a>, which could expand access to CAR-T cell therapy at both academic and community hospitals.Caribou Biosciences has received <a href="https://www.onclive.com/view/vispa-cel-shows-comparable-efficacy-durability-to-autologous-car-t-cell-therapy-in-r-r-b-cell-nhl">regenerative medicine advanced therapy designations</a> from the FDA for vispa-cel in the treatment of B-NHL. The company is now preparing for a pivotal phase 3 trial, as recommended by the FDA, to evaluate vispa-cel in <a href="https://investor.cariboubio.com/news-releases/news-release-details/caribou-biosciences-announces-positive-data-antler-phase-1-trial">approximately 250 CD19-naive patients</a> with large B-cell lymphoma who are ineligible for transplant or autologous CAR-T cell therapy. The trial will compare vispa-cel to standard immunochemotherapy, with <a href="https://www.onclive.com/view/vispa-cel-shows-comparable-efficacy-durability-to-autologous-car-t-cell-therapy-in-r-r-b-cell-nhl">progression-free survival as the primary endpoint</a>. These developments highlight the potential of vispa-cel to address an unmet need in the treatment of r/r B-NHL, particularly for patients who cannot undergo autologous CAR-T therapy or transplantation.

CRBU News